Funding
Seed · Biotech

Enodia Therapeutics raises €20.7m seed round

Elaia, Pfizer Ventures and Bpifrance joined investors backing therapies that target proteins as they are synthesized.

Updated Oct 16, 2026By RoundOS Funding desk

Enodia Therapeutics raised €20.7 million in seed financing on January 8. Participants included Elaia, Pfizer Ventures, Bpifrance, Wallonie Entreprendre, Argobio Studio, MACSF, the Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.

The company develops small-molecule therapies intended to degrade target proteins at the point of synthesis.

Funding history

Seed · This round€20.7M

Sources

  1. Enodia Therapeuticsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related